3 Numbers To Consider Before Buying AstraZeneca plc

Here are three numbers to assess when evaluating AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

There are always lots of numbers to evaluate when deciding whether or not to buy a particular share.

Today I’m going to look quickly at three numbers that should be considered by anyone thinking about investing in AstraZeneca (LSE: AZN) (NYSE: AZN.US).

9

That’s AstraZeneca’s price-to-earnings (P/E) ratio and it’s well below the FTSE 100 average of around 16.  That difference suggests that either the company’s earnings will be in serious decline for some time (not, perhaps, an uncommon opinion) or else the share price is undervalued. 

Boss Pascal Soriot has made some encouraging changes in his first year at AstraZeneca, such as a major shake-up of its senior management, and a new global strategy that’s clearly focused on R&D.

And there have also been some strategic ‘bolt-on’ acquisitions of companies with candidate products that AstraZeneca can potentially bring to market much faster than it could develop from scratch.

If you believe the company will be able to re-fill its dwindling product pipeline, and that it can develop a range of new treatments that will generate serious revenue, then that P/E of 9 suggests that AstraZeneca might currently be something of a bargain.

6

That’s AstraZenca’s current percentage yield — around double the FTSE 100 average, and substantially more than you can get from a savings account.

So, even if AstraZeneca’s share price fails to sparkle for some time, a dividend income of 6% on your investment is not to be sniffed at in the meantime.

Of course, the dividend needs to be sustainable. AstraZeneca’s current dividend policy is to maintain or grow the dividend within a limit of two times coverage by core earnings.

Given that it will take some time for new products to come to market, dividend growth may not be realistic for a few years yet. But so long as earnings don’t decline significantly, it should at least be maintainable.

21,000,000,000

That’s the consensus analyst forecast of the number of US dollars AstraZeneca will be generating in revenue in 2018.  $21bn may well seem a huge amount, but it’s 25% lower than the $28bn of 2012. It’s hardly encouraging to think that the company will be bringing in substantially less money in five years’ time than it did last year.

However, back in March, when it outlined its new strategy to “return to growth” and “achieve scientific leadership“, AstraZeneca said

Based on our focused investment in key growth platforms and our pipeline, we believe we can significantly exceed current market consensus for 2018 revenues of $21.5 billion.

Of course, “significantly exceed” is a somewhat imprecise term, but if that belief is justified, AstraZeneca’s future may be rather brighter than the market thinks, albeit that the light may be at the end of quite a long tunnel.

So there you have them — three numbers which may or may not have some bearing on whether you buy shares in AstraZeneca.

What next?

AstraZeneca is just one of eight dividend-paying blue chips that are firm favourites of investment guru Neil Woodford,  who has a remarkable track record of picking winners.

If you want to know about the other top-quality shares that Woodford currently favours, get your copy of the FREE Motley Fool report, 8 Shares Held By Britain’s Super Investornow!

> Jon does not own any share mentioned in this article.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »